Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19, virus identified
Conditions
Interventions
Intervention 1: Control group: standard approved treatment regimen for COVID-19, including famotidine, cetirizine, N-acetylcysteine, bromhexine, naproxen, and fluticasone inhaler for 7 days. Interven
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: People over the age of 65 who are in high-risk groups (with a history of high blood pressure, diabetes, BMI> 30, COPD, cancer, and etc.) Confirmation of the diagnosis of COVID-19 by chest CT scan and/or rt-PCR Signing an informed consent form
Exclusion criteria
Exclusion criteria: History of allergies to these drugs Use arbidol before hospitalization Pregnant women Respiratory failure and need for mechanical ventilation Renal and/or hepatic failure Anemia and thrombocytopenia Coagulopathy Autoimmune or immune deficiency disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of the removal of the symptoms. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.;Hospitalization required. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.;Life-threatening conditions. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic.;Death. Timepoint: Up to 1 month after the end of the study. Method of measurement: Examination of the patients by infectious disease specialists in an outpatient clinic. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Barary
Babol University of Medical Sciences
Outcome results
None listed